In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.
Tuesday, November 3rd
CELMoD Mechanisms and Immune Function in Multiple MyelomaCancerNetwork (EUA) · 15:19 OutrasEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith introduce cereblon E3 ligase modulators (CELMoDs) and discuss their dual activity in multiple myeloma.
Targeted scan detects hidden multiple myeloma missed by standard imagingMedical Xpress (Internacional) · 15:00 OutrasInternacional
Tocilizumab Prophylaxis, Caregiver Readiness, and Chair Time Shape Community Bispecific Programs in R/R MyelomaOncLive (EUA) · 08:00 Doentes e associaçõesEUACommunity hematologists/oncologists discussed bispecific antibody integration in community practice for relapsed/refractory multiple myeloma.
Evidence Supporting MRD Negativity as a Prognostic and Regulatory Endpoint in Multiple MyelomaCancerNetwork (EUA) · 08:00 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael asks Dr. Scott Goldsmith to explain the evidence supporting the use of minimal residual disease (MRD) negativity as an endpoint for regulatory decision-making in multiple myeloma.
Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R MyelomaOncLive (EUA) · 08:00 Doentes e associaçõesEUAFaculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.
Published American recommendations for the management of renal transplantation in patients with plasmacytic disorders.InternationalMy Hematologia · 5 Sep 2025This article discusses how kidney transplantation can be an option for people with multiple myeloma and other diseases that damage the kidneys, but it still presents challenges. Read more →
T-Cell Fitness and Treatment Sequencing in Multiple MyelomaCancerNetwork (EUA) · 08:00 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how T-cell fitness may influence treatment sequencing in multiple myeloma, particularly as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies become increasingly important treatment options.
Multiple myeloma: new therapies raise discussion about the possibility of a cure for the diseaseVEJA (Brazil) · 08:00 TreatmentsBrazilPTImmunotherapies and other innovations are expanding the chances of deep and lasting responses.
Mabworks takes GPRC5D–BCMA–CD3 trispecific MBS314 into Phase I/II trial for relapsed myelomaAllSci (China) · 08:00 InvestigaçãoChina
Chongqing drugmaker launches China's first domestically developed BCMA/CD3 bispecific antibodyChina Daily (China) · 08:00 TratamentosChina
Advanced imaging tool improves detection of residual multiple myeloma diseaseNews-Medical (Internacional) · 08:00 TratamentosInternacionalA targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy.
Standing in the Gaap: Raising multiple myeloma awareness through artBristol Myers Squibb (Internacional) · 08:00 Doentes e associaçõesInternacionalMultiple myeloma survivors and caregivers helped shape a Brooklyn mural designed to bring their experiences, community connections and stories into public view.
MRD Negativity and Its Clinical Significance in Multiple MyelomaCancerNetwork (EUA) · 08:00 InvestigaçãoEUAIn this segment, Dr. Joseph Mikhael, Dr. Paul Richardson, and Dr. Scott Goldsmith introduce the relationship between minimal residual disease (MRD) negativity and cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting the role of MRD-negative complete response as an emerging regulatory endpoint.
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple MyelomaCancerNetwork (EUA) · 08:00 Acesso e saúde públicaEUAJoshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Imaging the Invisible: A New Precision Approach to Detecting Multiple MyelomaUniversity of Miami (EUA) · 08:00 InvestigaçãoEUAA phase 2 Sylvester trial found that CD38-targeted immunoPET can reveal active multiple myeloma missed by standard PET/CT.
Early Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific AntibodiesOncodaily (Reino Unido) · 08:00 TratamentosReino UnidoEarly Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific Antibodies / Bispecific antibodies, cancer, CAR-T, Headlines,
Targeting the circ_0042819-PLA2G6 axis sensitizes multiple myeloma to proteasome inhibitors through ferroptosis inductionNature (Reino Unido) · 08:00 Doentes e associaçõesReino UnidoMultiple myeloma (MM) is a refractory plasma cell neoplasm characterized by frequent development of drug resistance, leading to poor clinical outcomes. Activation of ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, has emerged as a promising cancer therapeutic strategy. In this study, we…
High-Risk Multiple Myeloma Linked to Earlier CAR-T Cell FailureEMJ (Reino Unido) · 08:00 TratamentosReino UnidoHigh-risk multiple myeloma features were associated distinct patterns of treatment failure after cilta-cel.
Monday, 02/11
Frontline Treatment in Multiple Myeloma Is ChangingMedPage Today (EUA) · 08:00 TratamentosEUAExperts discuss the broader use of four-drug regimens and whether treatment can be shortened
Sunday, November 1st
Myeloma Is Many Diseases, and Treatment Must Reflect ThatThe American Journal of Managed Care (EUA) · 07:00 TratamentosEUANikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.
Friday, October 30th
Multiple myeloma and plasma cell disordersNature · 22:46 InvestigaçãoThis Collection invites research in the field of multiple myeloma and plasma cell disorders.
Annecy. Multiple myeloma: “This cancer is treatable but not curable.Le Dauphiné Libéré · 15:53 Patients and associationsFROn November 14th, the French Association of Multiple Myeloma Patients organizes in Annecy its 21st information day dedicated to this cancer of the...
Thursday, October 29th
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?CancerNetwork (EUA) · 17:09 TratamentosEUA“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Tecvayli monotherapy approved in EU for relapsed myeloma careRare Cancer News (Reino Unido) · 16:16 Acesso e saúde públicaReino UnidoThe EU has approved Tecvayli as a standalone injection for people whose myeloma has returned after one prior line of treatment.
Multiple myeloma: Cancer patient with 12 tumors finds hope as treatments advancefirstcoastnews.com (EUA) · 07:00 Doentes e associaçõesEUA
Dr. Rahul Banerjee on the future of myeloma careFred Hutchinson Cancer Center (Reino Unido) · 07:00 TratamentosReino UnidoRahul Banerjee, MD, FACP joins Petros Grivas, MD, PhD to discuss how CAR T cell-therapy and bispecific antibodies are changing myeloma care, ongoing Fred Hutch trials, working with community oncologists, and the team approach behind it all.
Starton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD in Combination with Novel CAR-T Therapy for Multiple MyelomaBusiness Wire (Internacional) · 07:00 TratamentosInternacional
